Late‐Onset Invasive Aspergillosis With Pituitary Involvement and Dysfunction Following CD19 Chimeric Antigen Receptor T‐Cell Therapy

Introduction Invasive fungal infection (IFI) after chimeric antigen receptor (CAR) T‐cell therapy is less common than bacterial and viral infections, but can be fatal once it develops. As most cases occur within 30 days after CAR T‐cell infusion, late‐onset IFI—particularly mould infection—appears to be under‐recognised. Discussion We report an illustrative case of pituitary aspergillosis developing as late as one year after CD19 CAR T‐cell therapy, highlighting a persistent risk in certain patients with delayed immune reconstitution. Conclusion This case underscores the need for continued vigilance and individualised antifungal strategies to prevent IFI beyond the early post‐infusion period. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission.